The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 181-185

  Pater, J L ^a   Lofters, W S ^b   Zee, B ^a   Dempsey, E ^c   Walde, D ^d   Moquin, J P ^e   Wilson, K ^f   Hoskins, P ^f   Guevin, R M ^g   Verma, S ^h   Navari, R ⁱ   Krook, J E ^j   Hainsworth, J ^k   Palmer, M ^a   Chin, C ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b Cancer Centre of South Eastern Ontario   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Group Health Centre   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g UNIVERSITY OF MONTREAL   (Canada)

^h ORCC   (Canada)

ⁱ Simon Williamson Clinic   (United States)

^j Duluth CCOP   (United States)

^k Sarah Cannon Cancer Center   (United States)

more..

Author keywords

5 HT3 antagonists; chemotherapy; clinical trial; emesis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; ONDANSETRON; ANTIEMETIC AGENT; INDOLE DERIVATIVE; QUINOLIZINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING; CHEMICALLY INDUCED DISORDER; MULTICENTER STUDY;

ANTIEMETICS; FEMALE; HUMANS; INDOLES; NAUSEA; ONDANSETRON; QUINOLIZINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0030611073     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008247830641     Document Type: Article

References (16)

1. Del Favero A, Roila F, Tonato M. Reducing chemotherapy-induced nausea and vomiting. Drug Safety 1993; 9: 410-28.
2. Osaba D, Warr DG, Fitch MI et al. Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: A consensus. Can J Oncol 1995; 5: 381-400.
3. Latreille J, Johnston D, Laberge F et al. Use of granisetron and dexamethasone on day 2-7 following high-dose cisplatin. Support Care Cancer 1995; 3: 339 (Abstr).
4. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991; 27 (Suppl 1): S9-S11.
5. Navari R, Madajewicz F, Anderson et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: A large, multi-centre, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13: 2408-16.
6. Kaizer L, Warr D, Hoskins P et al. The effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050-7.
7. Stewart A, Mcquade B, Cronje JD et al. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology 1995; 52: 202-10.
8. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: Double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108-14.
9. Moreno I, Rosell R, Albert A et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992; 28A: 1344-7.
10. Jones AL, Hill AS, Soukop M et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483-7.
11. Lofters WS, Zee B. Dolasetron vs. ondansetron with and without dexamethasone in the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Support Care Cancer 1995; 3: 339.
12. Willan AR, Warr D, Pater JL et al. Methodological issues in antiemetic studies. In Osoba D (ed): Effect of Cancer on Quality-of-Life. Boca Raton, FL: CRC 1991; 229-49.
13. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: A review. Ann Oncol 1991; 2: 107-14.
14. Aaronson N, Ahmedzai S, Bergunder B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualify-of-life instrument, for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
15. SAS Institute Inc. SAS/STAT® User's Guide, Version 6, Fourth Edition, Volume 1, Volume 2. Cary, NC: SAS Institute Inc. 1989; 943 pp, 846 pp.
16. Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific quality-of-life questionnaire. J Clin Epidemiol 1994; 47: 81-7.